Dr. Rich Murray has over 30 years of industry experience in the fields of immunology and cancer, centered on protein and antibody therapeutics research, from early-stage innovations through product approvals. He is currently senior advisor to Qiming Ventures USA, and was most recently CEO of Jounce Therapeutics, an immuno-oncology focused company. He led the company through private and public financings and numerous substantial business deals. He was SVP of Biologics and Vaccines at Merck establishing their Biologics capabilities and was instrumental in the research and development of Keytruda. Previously he was CSO at Protein Design Labs overseeing antibody technologies, pipeline, and manufacturing prior to acquisition by Abbott, now AbbVie. He was a founder and VP of Research at Eos Biotech leading to its acquisition by Protein Design Labs. Rich has served on both public and private company Boards. He received his PhD in immunology and microbiology at the University of North Carolina where he was a Lineberger Cancer Research fellow and did his post-doctoral research at DNAX Research Institute.  

Dr. Lazar is Co-Founder and Chief Scientific Officer at Dualitas Therapeutics. Prior to Dualitas he led research groups at Genentech, Eli Lilly, and Xencor. Together with colleagues, Dr. Lazar has developed multiple technologies for optimizing antibodies and therapeutic proteins, and contributed to numerous clinical stage molecules including several approved drugs. He is an inventor of over 30 patents and has authored over 40 scientific publications in the fields of protein design, biotherapeutic engineering, and drug discovery. Dr. Lazar holds a BS in Molecular & Cell Biology with Chemistry Honors from Penn State and a PhD in Molecular & Cell Biology from UC Berkeley, and was a Jane Coffin Childs Fellow at the University of Cambridge.

Forbes Huang is Co-Founder, Chief Operating Officer and Chief Business Officer of Dualitas Therapeutics overseeing operations, business development, portfolio management, investor relations, human resources, and finance for the Company. He was previously CEO for a Novo Holdings startup (acquired by Insmed); Senior Vice President of Corporate Development at Gyroscope Therapeutics (acquired by Novartis), and Vice President of Business Development & Operations at IVERIC bio (acquired by Astellas). He began his career in investment banking at Morgan Stanley advising on biotech IPOs, M&A, and financing, and private equity investing at H.I.G. Capital. 

Forbes received his MBA from The Wharton School of the University of Pennsylvania with highest distinction as a Palmer Scholar. He is an appointed Senior Fellow with The Wharton School and served as Executive-in-Residence at the Penn Center for Innovation. He earned dual bachelor’s degrees in Finance and Economics from New York University’s Stern School of Business graduating summa cum laude.